MSRA

Across TCGA pan-cancer cohorts, MSRA mass-spec protein is linked to patient survival in 7 of 34 cancer types, making it a survival-associated MSRA data layer compared with 27 for mass-spec protein and 2 for mutation status.

The strongest signal is observed in clear cell renal cell carcinoma (CCRCC), where higher MSRA mass-spec protein is associated with better disease-free survival. In most high-consensus cancer types, elevated MSRA expression acts as an unfavorable survival marker, although some lineages such as CCRCC and PDAC show a favorable association.

CCRCC, LUAD, and PDAC are the cancer types where MSRA mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
CCRCC	DFS	Quartile	All	0.857	0.506	.001	72	view →
LUAD	OS	Quartile	III,IV	0.386	0.867	.012	21	view →
PDAC	OS	Median	II,III,IV	0.548	0.277	.004	10	view →
LSCC	DFS	Median	II,III,IV	0.540	0.822	.016	7	view →
GBM	DFS	Quartile	All	0.594	0.886	.013	4	view →
UCEC	DFS	Median	III,IV	0.408	0.915	.015	4	view →
HNSC	DFS	Tertile	II,III,IV	0.897	0.989	.040	2	view →

Pink = unfavorable, green = favorable. Showing the 7 strongest of 7 lineages.

MSRA–CCRCC (DFS)

Open the CCRCC breakdown →